Myroxylon pereirae (balsam of Peru): Still worth testing?


Journal

Contact dermatitis
ISSN: 1600-0536
Titre abrégé: Contact Dermatitis
Pays: England
ID NLM: 7604950

Informations de publication

Date de publication:
Sep 2021
Historique:
revised: 17 03 2021
received: 09 11 2020
accepted: 19 03 2021
pubmed: 23 3 2021
medline: 17 12 2021
entrez: 22 3 2021
Statut: ppublish

Résumé

Because Myroxylon pereirae (MP), or balsam of Peru, is nowadays almost not used "as such," and fragrance mix 1 (FM1) apparently is more sensitive in detecting fragrance allergy, the usefulness of testing MP in baseline series was recently questioned. Identification of the number of clinically relevant patch test reactions to MP not detected by FM1. Retrospective analysis of 12 030 patients patch tested with MP and FM1 for contact dermatitis between January 2018 and December 2019 in 13 Italian dermatology clinics. Four hundred thirty-nine patients (3.6%) had a positive patch test reaction to MP; 437 (3.6%) had a positive patch test reaction to FM1. Positive reactions to both MP and FM1 were observed in 119 subjects (1.0%), 310 (2.6%) reacted to MP only, 304 (2.5%) to FM1 only, 5 to MP and sorbitan sesquioleate (SSO), 9 to FM1 and SSO, and 5 to MP, FM1, and SSO. Single sensitizations were clinically relevant in 75.2% of cases for MP (62.9% current, 12.3% past) and 76.3% for FM1 (70.1% current, 6.2% past). Based on our results, MP appears to be still worth testing along with FM1 in baseline series, because it allows detection of a remarkable number of fragrance allergies, often relevant, which would be otherwise missed.

Sections du résumé

BACKGROUND BACKGROUND
Because Myroxylon pereirae (MP), or balsam of Peru, is nowadays almost not used "as such," and fragrance mix 1 (FM1) apparently is more sensitive in detecting fragrance allergy, the usefulness of testing MP in baseline series was recently questioned.
OBJECTIVES OBJECTIVE
Identification of the number of clinically relevant patch test reactions to MP not detected by FM1.
METHODS METHODS
Retrospective analysis of 12 030 patients patch tested with MP and FM1 for contact dermatitis between January 2018 and December 2019 in 13 Italian dermatology clinics.
RESULTS RESULTS
Four hundred thirty-nine patients (3.6%) had a positive patch test reaction to MP; 437 (3.6%) had a positive patch test reaction to FM1. Positive reactions to both MP and FM1 were observed in 119 subjects (1.0%), 310 (2.6%) reacted to MP only, 304 (2.5%) to FM1 only, 5 to MP and sorbitan sesquioleate (SSO), 9 to FM1 and SSO, and 5 to MP, FM1, and SSO. Single sensitizations were clinically relevant in 75.2% of cases for MP (62.9% current, 12.3% past) and 76.3% for FM1 (70.1% current, 6.2% past).
CONCLUSIONS CONCLUSIONS
Based on our results, MP appears to be still worth testing along with FM1 in baseline series, because it allows detection of a remarkable number of fragrance allergies, often relevant, which would be otherwise missed.

Identifiants

pubmed: 33748955
doi: 10.1111/cod.13839
pmc: PMC8453940
doi:

Substances chimiques

Balsams 0
Hexoses 0
sorbitan sesquioleate 0W8RRI5W5A
Peruvian balsam 8P5F881OCY

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

269-273

Investigateurs

Alessandro Borghi (A)
Katharina Hansel (K)
Giovanni Damiani (G)
Ilaria Trave (I)
Emanuela Martina (E)
Giacomo Dal Bello (G)
Massimo Gola (M)
Maria L Musumeci (ML)
Viviana Piras (V)

Informations de copyright

© 2021 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd.

Références

Contact Dermatitis. 2019 Apr;80(4):208-216
pubmed: 30378136
Br J Dermatol. 2018 Mar;178(3):776-780
pubmed: 28960261
Contact Dermatitis. 2009 Oct;61(4):217-23
pubmed: 19825093
Contact Dermatitis. 2014 May;70(5):276-81
pubmed: 24731084
G Ital Dermatol Venereol. 2019 Jun;154(3):227-253
pubmed: 30717577
Contact Dermatitis. 2010 Aug;63(2):77-84
pubmed: 20573166
Contact Dermatitis. 2001 May;44(5):304-7
pubmed: 11298698
Contact Dermatitis. 2011 Nov;65(5):266-75
pubmed: 21943251
Contact Dermatitis. 2003 Dec;49(6):287-9
pubmed: 15025700
Nat Prod Res. 2020 Apr 21;:1-6
pubmed: 32316792
Contact Dermatitis. 2019 Jun;80(6):335-353
pubmed: 30843216
Contact Dermatitis. 1997 Jun;36(6):291-6
pubmed: 9237007
Contact Dermatitis. 2021 Sep;85(3):269-273
pubmed: 33748955
Br J Dermatol. 1996 Sep;135(3):419-22
pubmed: 8949436
Contact Dermatitis. 2010 Nov;63(5):254-61
pubmed: 20731693
Contact Dermatitis. 2019 Dec;81(6):454-456
pubmed: 31328272
Sci Total Environ. 2020 Nov 10;742:140640
pubmed: 32721747

Auteurs

Fabrizio Guarneri (F)

Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

Monica Corazza (M)

Sezione di Dermatologia, Dipartimento di Scienze Mediche, Università degli Studi di Ferrara, Ferrara, Italy.

Luca Stingeni (L)

Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy.

Cataldo Patruno (C)

Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.

Maddalena Napolitano (M)

Department of Health Sciences "V. Tiberio", University of Molise, Campobasso, Italy.

Paolo D M Pigatto (PDM)

IRCCS Istituto Ortopedico Galeazzi, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.

Rosella Gallo (R)

Section of Dermatology - Department of Health Sciences, University of Genoa, Ospedale Policlinico San Martino - IRCCS, Genoa, Italy.

Antonio Cristaudo (A)

UOSD Dermatologia MST, Ambientale, Tropicale e Immigrazione, Istituto Dermatologico San Gallicano (IRCCS), Rome, Italy.

Paolo Romita (P)

Section of Dermatology, Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy.

Annamaria Offidani (A)

Clinica Dermatologica, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy.

Donatella Schena (D)

Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.

Nicola Milanesi (N)

Allergological and Occupational Dermatology Unit, Department of Health Sciences, AUTC and University of Florence, Florence, Italy.

Giuseppe Micali (G)

Dermatology Clinic, University of Catania, PO G. Rodolico, AOU Policlinico-Vittorio Emanuele, Catania, Italy.

Myriam Zucca (M)

Dermatologic clinic, University Hospital S. Giovanni di Dio, Cagliari, Italy.

Caterina Foti (C)

Section of Dermatology, Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH